Geode Capital Management LLC Acquires 5,915 Shares of Amedisys, Inc. (NASDAQ:AMED)

Geode Capital Management LLC increased its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 573,020 shares of the health services provider's stock after acquiring an additional 5,915 shares during the quarter. Geode Capital Management LLC owned about 1.75% of Amedisys worth $52,040,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Diametric Capital LP lifted its position in shares of Amedisys by 26.3% during the 4th quarter. Diametric Capital LP now owns 9,476 shares of the health services provider's stock worth $860,000 after purchasing an additional 1,976 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Amedisys by 33.8% in the fourth quarter. National Bank of Canada FI now owns 74,400 shares of the health services provider's stock valued at $6,755,000 after acquiring an additional 18,808 shares during the period. Alliancebernstein L.P. grew its stake in shares of Amedisys by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 677,787 shares of the health services provider's stock worth $61,536,000 after acquiring an additional 13,587 shares during the last quarter. Highbridge Capital Management LLC increased its position in Amedisys by 18.0% during the fourth quarter. Highbridge Capital Management LLC now owns 381,123 shares of the health services provider's stock worth $34,602,000 after acquiring an additional 58,223 shares during the period. Finally, Norges Bank bought a new position in Amedisys during the fourth quarter worth $83,061,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Remove Ads

Analyst Ratings Changes

Separately, Stephens restated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $101.00.

Amedisys Stock Performance

AMED traded up $0.14 during trading on Tuesday, reaching $91.58. 111,386 shares of the company's stock were exchanged, compared to its average volume of 401,020. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a market capitalization of $3.00 billion, a P/E ratio of 36.34, a PEG ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $92.17 and a 200 day moving average price of $91.98.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. As a group, analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.